A phase II study of ruxolitinib in combination with azacytidine for MF Patients

[Paul123456]

bloodjournal.org/content/ea...

‘ A greater than 50% reduction in palpable spleen length at 24 weeks and at any time on the study was achieved in 62% and 71% of the evaluable patients, respectively. Among patients who achieved a >50% reduction in spleen length at 24 weeks, 95% had maintained this at 48 weeks. Notably, improvements in bone marrow reticulin fibrosis grade occurred in 57% of the patients at 24 months’

[bruddery]

Thanks Paul, You always manage to find encouraging articles. Very interesting and nice to know there is something else in the pipeline.

[Paul123456 in reply to bruddery]

Combo therapies are an interesting new development, the science is way beyond my pay grade but Ruxo’s anti inflammatory properties make some drugs more tolerable plus it appears to enhance efficacy of combining drug.

The difference between new drugs in trial now versus 10 years ago is very encouraging.........

[Bluetop]

Thanks for keeping on top of these developments Paul. It sounds more encoraging news